Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Tax Provisions (2014 - 2026)

Innoviva's (INVA) quarterly Tax Provisions came in at $48.0 million in Q1 2026, up 499.6% YoY from $8.0 million in Q1 2025, and up 93.42% on a QoQ basis from $24.8 million in Q3 2025.

Analysis

Innoviva (INVA) Tax Provisions (2014 - 2026) Analysis & Trends

Innoviva (INVA) has 11 years of Tax Provisions data on file, last reported at $48.0 million in Q1 2026.

  • Quarterly Tax Provisions rose 499.6% year-over-year to $48.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.7 million (up 315.06% YoY) and the FY2024 annual result came in at $26.6 million, up 1757.15% from the prior year.
  • Tax Provisions improved to $48.0 million in Q1 2026, from $24.8 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $63.1 million in Q3 2022 to a low of -$4.6 million in Q2 2024.
  • A 5-year average of $15.2 million and a median of $8.6 million in 2024 frame the typical range for Tax Provisions.
  • Annual changes were most pronounced in 2023 — Tax Provisions surged 600.0% — and 2024, when it plunged 202.09%.
  • Tracing INVA's Tax Provisions over 5 years: stood at $63.1 million in 2022, then slumped by 76.68% to $14.7 million in 2023, then tumbled by 34.72% to $9.6 million in 2024, then surged by 158.33% to $24.8 million in 2025, then surged by 93.42% to $48.0 million in 2026.
  • The last three Tax Provisions figures came in at $48.0 million (Q1 2026), $24.8 million (Q3 2025), and $8.9 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Taxes (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 292.00 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 230.90 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -59.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 15.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 75.45 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 13.31 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.90 Mn
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn -24.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -24.60 Mn
Mar 31, 2026 48.00 Mn
Sep 30, 2025 24.81 Mn
Jun 30, 2025 8.91 Mn
Mar 31, 2025 8.00 Mn
Sep 30, 2024 9.63 Mn
Jun 30, 2024 -4.60 Mn
Mar 31, 2024 8.60 Mn
Sep 30, 2023 14.71 Mn
Jun 30, 2023 4.53 Mn
Mar 31, 2023 6.30 Mn
Sep 30, 2022 63.10 Mn
Jun 30, 2022 -900,000.00
Mar 31, 2022 6.90 Mn
Sep 30, 2021 65.60 Mn
Jun 30, 2021 25.33 Mn
Mar 31, 2021 19.74 Mn
Dec 31, 2020 29.69 Mn
Sep 30, 2020 8.90 Mn
Jun 30, 2020 19.90 Mn